Plasma acylation-stimulating protein in coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 7, 1997, Pages 1239-1244

  Cianflone, Katherine ^a   Zhang, Xiao Jing ^a   Genest Jr , Jacques ^b   Sniderman, Allan ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Acylation stimulating protein; Coronary artery disease; HyperapoB

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACYLATION; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; OBESITY; PHENOTYPE; PRIORITY JOURNAL;

ACYLATION; ADULT; AGED; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BLOOD PROTEINS; COMPLEMENT C3A; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PHENOTYPE; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 0030877878     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sniderman AD, Brown BG, Stewart FF, Cianflone K. From familial combined hyperlipidemia to hyperapoB: unravelling overproduction of hepatic apoB lipoproteins. Curr Opin Lipidol. 1992;3:137-142.
2. Abdel-Fattah G, Fernandez ML, McNamara NJ. Regulation of guinea pig very low density lipoprotein secretion rates by dietary fat saturation. J Lipid Res. 1995;36:1188-1198.
3. Sniderman AD, Cianflone K. Metabolic disruptions in the adipocytehepatocyte fatty acid axis as causes of HyperapoB. Int J Obes Relat Metab Disord. 1995;19:S27-S33.
4. Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B, Monge JC, Bell A, Mulay S, Cianflone K. The adipsinacylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest. 1993;92:1543-1557.
5. Cianflone K, Roncari DAK, Maslowska M, Baldo A, Forden J, Sniderman AD. Adipsin acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry. 1994;33:9489-9495.
6. Sniderman AD, Julien P, Cianflone K. Peripheral triglyceride clearance, the adipsin-ASP pathway and type IV hyperlipoproteinemia. In: Bagdade JD, ed. Yearbook of Endocrinology. St. Louis, Mo: Mosby-Year Book Inc; 1995:xix-xxxvii.
7. Cianflone K, Vu H, Walsh M, Baldo A, Sniderman AD. The metabolic response of ASP to an oral fat load. J Lipid Res. 1989;30:1727-1733.
8. Sniderman AD, Cianflone K, Eckel RH. Levels of acylation stimulating protein in obese women before and after moderate weight loss. Int J Obesity. 1991;15:333-336.
9. Cianflone K, Kalant D, Marliss EB, Gougeon R, Sniderman AD. Response of plasma ASP to a prolonged fast. Int J Obesity. 1995;19:604-609.
10. Sniderman AD, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis. 1991;89:109-116.
11. Havel R, Eder H, Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
12. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL, Albers JJ, Marcovina SM. Measurement of apolipoproteins A-I and B during the National Health and Nutrition Examination Survey (NHANES) III. Clin Chem. 1994;40:1915-1920.
13. Kohen-Avramoglu R, Sniderman AD, Cianflone K. The role of the neutral lipid accessible pool in the regulation of secretion of B100 lipoprotein particles by HepG2 cells. J Lipid Res. 1995;36:2513-2528.
14. Bouthillier D, Sing CF, Davignon J. Apolipoprotein E phenotyping with a single gel method-application to the study of informative matings. J Lipid Res. 1983;24:1060-1069.
15. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983;24:147-155.
16. Davignon J, Gregg R, Sing C. Apolipoprotein E polymorphism and atherosclerosis. Arterioscler Thromb. 1988;8:1-21.
17. Yasruel Z, Cianflone K, Sniderman AD, Rosenbloom M, Walsh M, Rodriguez MA. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids. 1991;26:495-499.
18. Germinario R, Sniderman AD, Manuel S, Pratt S, Baldo A, Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism. 1993;40:574-580.
19. Maslowska M, Sniderman AD, Germinario R, Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes. 1997;21:261-266.
20. 19a. Tao Y, Cianflone K, Sniderman AD, Colby-Germinario SP, Germinario RJ. Acylation-slimulaling protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta. 1997;1344:221-229.
21. Cianflone K, Maslowska M, Sniderman AD. Impaired response of fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein. J Clin Invest. 1990;85:722-730.
22. Kalant D, Zhang ZJ, Cianflone K, Sniderman AD. Specific binding of ASP to human fibroblasts and human adipocytes. Clin Invest Med. 1995;18(suppl B):B10.
23. Baldo A, Sniderman AD, St-Luce S, Zhang XJ, Cianflone K. The signal transduction pathway of acylation stimulating protein: involvement of protein kinase C. J Lipid Res. 1995;36:1415-1426.
24. Cianflone K, Maslowska M. Differentiation induced production of ASP in human adipocytes. Eur J Clin Invest. 1995;25:817-825.
25. Walsh MJ, Sniderman AD, Cianflone K, Vu H, Rodriguez MA, Forse RA. The effect of ASP on the adipocyte of the morbidly obese. J Surg Res. 1989;46:470-473.
26. Genest J, Sniderman AD, Cianflone K, Teng B, Wacholder S, Marcel YL, Kwiterovich PO Jr. Hyperapobetalipoproteinemia: plasma lipoprotein responses to oral fat load. Arteriosclerosis. 1986;6:297-304.
27. Cabezas MC, de Bruin TW, Lock LA, et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 1993;42:497-503.
28. Reynisdottir S, Eriksson M, Angelin B, Amer P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest. 1995:95:2161.
29. Teng B, Forse A, Rodriquez MA, Sniderman AD. Adipose tissue glyceride synthesis in patients with hyperapobetalipoproteinemia. Can J Pharmacol Physiol. 1988;66:239-242.
30. Rubinsztein D, Cohen J, Berger M, van der Westhuyzen D, Coetzee G, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest. 1990;86:1306-1312.
31. Chait A, Albers J, Brunzell JD. Very low density lipoprotein over-production in genetic forms of hypertriglyceridemia. Eur J Clin Invest. 1980;10:17-22.
32. Brenninkmeijer B, Stuyt P, Demacker P, Stalenhoef A, van't Laar A. Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. J Lipid Res. 1987;28:361-370.
33. Stalenhoef A, Malloy M, Kane J, Havel R. Metabolism of apolipoproteins B48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest. 1986;78:722-728.